Xin Lang Zheng Quan·2026-01-09 01:23Group 1 - The core viewpoint of the news is that Tiger Med's stock performance and financing activities indicate a stable yet cautious market position, with a slight increase in stock price and a low financing balance relative to market capitalization [1][2]. Group 2 - On January 8, Tiger Med's stock rose by 0.51%, with a trading volume of 645 million yuan. The net financing purchase was 4.74 million yuan, with a total financing and securities balance of 727 million yuan [1]. - The financing balance of Tiger Med is 724 million yuan, accounting for 1.62% of its circulating market value, which is below the 30th percentile level over the past year, indicating a low financing position [1]. - In terms of securities lending, on January 8, Tiger Med repaid 24,100 shares and sold 300 shares, with a selling amount of 18,200 yuan. The securities lending balance is 2.78 million yuan, which is above the 60th percentile level over the past year, indicating a relatively high position [1]. Group 3 - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, provides professional clinical research services for domestic and international pharmaceutical and health-related products. Its main business revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [2]. - As of September 30, 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3].